AML 16: Evalution of the prognostic impact and optimal use of immunophenotypic monitoring of residual disease in patients with acute myeloid lukaemia recruited to AML 16

Project: Research

Participants

Short titleAML 16: Evalution of the prognostic impact and optimal use of immunophenotypic monitoring of residual disease in patients with acute myeloid lukaemia recruited to AML 16
StatusFinished
Effective start/end date1/04/0731/03/12